832-497-2220 [email protected]

Pediatric Drug

China is currently the world’s second-largest pediatric drug market. With the implementation of China’s “Two-child” policy, it is predicted that the child population is expected to reach 269 million by 2024. The children’s drug market only accounts for about 5% of the entire pharmaceutical industry in China, while the children’s population accounts for about 18%. The children’s drug market is far from saturated and the prospect is broad. From 2018 to 2019, along with policy supports such as encouraging research and development, prioritizing reviews, strengthening hospital equipment, China’s pediatric drug market will continue to expand at a high speed.

Submitted Projects:

Project ID: PED101

Category: Pediatric Drug

Keyword: Novel bioactive lipid compounds

Project/Product Summary:

Project PED101 develops new medicines for unmet needs in dermatological diseases. The compounds under development are based on a novel bioactive lipid platform. These molecules are crucial to the pathways of several conditions including skin disorders such as atopic dermatitis (AD). The Company’s lead compound is being explored clinically as both a topical cream for mild to moderate AD (Phase 3) and separately as an oral capsule in moderate to severe AD (Phase 2b). DS holds multiple patents and pending applications protecting the product and its clinical uses.

Indications: Atopic Dermatitis in Children and Adolescents

Stage: Clinical Phase II/Phase III

Partnering Objectives: Fundraisingd US$48 million for Phase III of the experiment

Country: Ireland

Project ID: PED102

Category: Pediatric Drug

Keyword: Glycopyrronium Bromide Liquid

Project/Product Summary:

The company develops product Glycopyrronium Bromide is proven to be effective and well-tolerated in treating severe hypersalivation in children and adolescents with cerebral palsy or other neurological conditions; it is available in a liquid formulation to provide maximal dosing flexibility and tolerability. Licensed indications include: Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders

Indications: Excessive saliva production

Stage: public listed

Partnering Objectives: Commercial cooperation, product Licensing

Country: UK

Project ID: PED103

Category: Pediatric Drug

Keyword: SVLP technology

Project/Product Summary:

Project PED103 is developing next-generation synthetic vaccines to prevent infectious diseases and treat chronic diseases. The company has two proprietary technologies: Synthetic Antigen Mimetics (SAMs) and a Synthetic Virus-Like Particle (SVLP) platform to deliver and present SAMS to the immune system. Manufactured synthetically, these vaccines are inexpensive, easy-to-produce, modular, and customisable. They do not require the addition of adjuvants. Based on strong preclinical data and a validated target, the lead asset, V-306, is about to enter Phase 1 in RSV. Success in the project will provide a proof-of-concept to leverage the promising pipeline in infectious diseases and oncology. Virometix is seeking a licensing partner for China and/or a Chinese strategic investor for a co-development agreement.

Indications: Infectious diseases, respiratory and tumor diseases

Stage: Preclinical

Partnering Objectives: Fundraising, business cooperation

Country: Switzerland

Potential Chinese Partners: